CNS Pharmaceuticals, a biotechnology company specializing in the development of novel treatments for brain tumors, completed an agreement with Houston Pharmaceuticals, Inc. ("HPI") to obtain the rights to a worldwide, exclusive royalty-bearing, license for the chemical compound commonly known as Berubicin.
US-based Dicerna Pharmaceuticals and Novo Nordisk have signed a deal worth up to around $607m to discover and develop drugs for liver-related cardio-metabolic diseases.
Aerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, announced the signing of an agreement (the “Agreement”) for the acquisition of Avizorex Pharma, S.L. (“AVX Pharma” or “AVX”), a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease.
Alkermes has signed an agreement to acquire biopharmaceutical company Rodin Therapeutics in a deal valued at around $950m.
Roche has agreed to acquire US-based clinical-stage biotechnology company Promedior in a deal valued at around $1.39bn.
EpicentRx, a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced today that it has raised a $35 million Series D financing using the Silicon Valley based life-science focused investment bank, Biotech Alliances International.
Finch Therapeutics Group, Inc. (“Finch”) and Takeda Pharmaceutical Company Limited (“Takeda”; TSE:4502/NYSE:TAK) announced today the expansion of their collaboration to develop microbiome-based therapeutics using Finch’s Human-First Discovery platform.
RDD Pharma, a company focused on orphan and innovative therapies for gastrointestinal disorders entered into a non-binding letter of intent (LOI) to acquire Naia Rare Diseases ("Naia"), a biopharmaceutical company developing drugs for Short Bowel Syndrome ("SBS") and other rare gastrointestinal diseases.
COI Pharmaceuticals announced that Merck has agreed to acquire Calporta Therapeutics in a deal valued at around $576m.
NEC has the option for development and commercialization rights to the program worldwide, except for China and other Asian territories outside of Japan
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.